Meta-Analysis
Copyright ©The Author(s) 2024.
World J Hepatol. Mar 27, 2024; 16(3): 465-476
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.465
Table 1 The basic characteristics of the enrolled studies included in this meta-analysis
Ref.
Ateş et al[8]
Jin et al[9]
Gong et al[10]
Liu et al[11]
Zhu et al[12]
Kim et al[13]
Cho et al[14]
Lee et al[15]
Chen et al[16]
Li et al[17]
Liang et al[18]
Year20112012201520152016201920192019202020202021
LocationTurkeyChinaChinaChinaChinaKoreaKoreaKoreaChinaUnited StatesChina
StudyProspective studyProspective studyProspective studyProspective studyRetrospective studyRetrospective studyRetrospective studyRetrospective studyRetrospective studyRetrospective studyProspective study
JournalWorld J GastroenterolPLoS OneTransplant ProcJ Interferon Cytokine ResDrug Des Devel TherClin Mol HepatolJ Clin GastroenterolClin Mol HepatolBMC GastroenterolLiver IntGastroenterol Res Pract
Therapy regimenPEG-IFNNucleos(t)ide analoguesPEG-IFNNucleos(t)ide analoguesNucleos(t)ide analoguesNucleos(t)ide analoguesNucleos(t)ide analoguesNucleos(t)ide analoguesNucleos(t)ide analoguesNucleos(t)ide analoguesPEG-IFN
MaleCHB with NAFLD953220234291171504312695
CHB82853812411193331464321182
FamaleCHB with NAFLD1233111719698920136112
CHB36320823692331051315737
AgeCHB with NAFLD50.5 ± 8.739.56 ± 11.8730.3 ± 7.437.70 ± 7.9039.26 ± 10.3951.0 (42.0-56.3)52.0 ± 9.445 (36–51)39 (31-34)47.7 ± 12.520.87 ± 1.96
CHB35.2 ± 8.939.55 ± 7.8325.1 ± 7.837.35 ± 8.4939.61 ± 10.8751.0 (43.3-57.0)54.0 ± 8.841 (32–48)38.5 (31–44)45.5 ± 14.629.50 ± 5.47
BMICHB with NAFLD32.9 ± 3.126.35 ± 4.1925.3 ± 2.128.16 ± 1.4326.29 ± 3.9924.7 (22.3-26.724.5 ± 3.5NA25.0 ± 3.025.4 ± 4.3NA
CHB25.7 ± 3.324.26 ± 3.4122.5 ± 2.922.06 ± 1.0222.50 ± 2.8522.5 (20.4-24.4)23.8 ± 3.2NA23.0 ± 3.023.8 ± 4.020.87 ± 1.96
ALTCHB with NAFLD128.3 ± 18.9143.3 ± 82.1171.68 ± 46.23227.70 ± 121.14179.87 ± 78.5056 (38-94)NA71 (32–114)99 (68-154)60 (15 - 1525)NA
CHB139.2 ± 52.5157.1 ± 108.3159.18 ± 45.12229.95 ± 137.36187.95 ± 79.8856 (34-90)NA94 (45–171)124 (79–216)50 (14 - 1079)257.39 ± 175.17
ASTCHB with NAFLD90.7 ± 34.870.2 ± 33.759.66 ± 13.81183.23 ± 103.70NANANA53 (36–86)61 (38-84)37 (13 - 1465)NA
CHB107.0 ± 40.393.5 ± 72.356.63 ± 13.13167.60 ± 85.07NANANA85 (51–153)72 (45–137)35 (12 - 863)126.72 ± 79.55
GGTCHB with NAFLD49.8 ± 29.895.2 ± 73.242.92 ± 14.8398.75 – 19.90NANANANANANANA
CHB50.0 ± 44.077.2 ± 89.746.05 ± 11.3651.41 – 5.46NANANANANANANA
TBCHB with NAFLDNANANANANA0.8 (0.7-1.1)1.0 ± 0.4NA0.8 (0.6-1.0)1.3 ± 3.0NA
CHBNANANANANA0.9 (0.7-1.2)1.1 ± 0.4NA1.0 (0.7–1.2)1.3 ± 2.7NA
ALBCHB with NAFLDNANANANANA4.2 (4.0-4.4)4.18 ± 0.34.2 (3.8–4.4)NA4.0 ± 0.6NA
CHBNANANANANA4.2 (3.9-4.4)4.25 ± 0.44.0 (3.7–4.3)NA3.9 ± 0.6NA
TCCHB with NAFLD192.2 ± 28.084.6 ± 14.480.28 ± 7.92115.02 ± 968.04 ± 1.26178 (151-204)NA176 (155–203)NA181 ± 40NA
CHB178.0 ± 27.481.0 ± 14.478.66 ± 5.7681.18 ± 8.166.96 ± 17.46170 (151-190)NA159 (137–179)NA177 ± 410.56 ± 0.45
TGCHB with NAFLD188.3 ± 52.034.2 ± 14.427.54 ± 6.8448.06 ± 10.9832.4 ± 16.2NANA103 (81–137)NA189 ± 153NA
CHB114.2 ± 44.221.6 ± 919.98 ± 7.0225.92 ± 2.8823.94 ± 11.52NANA80 (63–109)NA86 ± 424.68 ± 0.80
HDLCHB with NAFLDNANANANA15.48 ± 6.12NANA44.4 (35.4–54.4)NA40 ± 9NA
CHBNANANANA19.26 ± 6.3NANA48.3 (39.4–59.4)NA58 ± 19NA
LDLCHB with NAFLDNANANANA41.58 ± 12.96113 (93-129)NA105 (87–129)NA111 ± 37NA
CHBNANANANA38.88 ± 12.24101 (80-126)NA90 (75–108)NA106 ± 32NA
GlucoseCHB with NAFLD102.7 ± 27.74.8 ± 0.65.46 ± 1.37NA5.11 ± 0.8596.0 (89.3-107.0)NA103 (92–117)NA115 ± 37NA
CHB96.7 ± 19.04.5 ± 0.55.07 ± 0.92NA4.89 ± 0.809 4.0 (87.3-102)NA98 (90–108)NA105 ± 26NA
Quality scores67766786766